For compounded tirzepatide, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
My buddy Dave in Phoenix put it perfectly over lunch last February, picking at a plate of chicken he’d barely touched. “I lost 30 pounds on semaglutide and the food just stopped mattering. Like, all food. My wife made her green chile enchiladas and I felt nothing.” Dave, 42, had been on semaglutide for eight months, down from 248 to 218 pounds. He switched to tirzepatide in March. By June he’d dropped another 22 pounds, and he was actually cooking again. “I still eat less,” he told me, “but I give a damn about what I’m eating.” That’s the comparison in a nutshell, though the full picture is more nuanced than one guy’s enchilada epiphany.
I used both. Semaglutide for nine months in 2023, tirzepatide for seven months in 2024. This is the side-by-side I wish someone had handed me before either decision.
Quick compliance note: compounded versions of these medications are not FDA-approved. The branded products (Wegovy and Ozempic for semaglutide, Zepbound and Mounjaro for tirzepatide) are. Compounded preparations come from licensed 503A/503B compounding pharmacies for individual patients based on prescriber clinical judgment. Different regulatory pathway. Same active molecules.
One Receptor vs Two: Why It Actually Matters
Semaglutide targets the GLP-1 receptor. Tirzepatide targets both GLP-1 and GIP receptors. This isn’t branding fluff. It’s a genuine biological difference, and it shows up in the data.
The SURPASS and SURMOUNT trials for tirzepatide showed average weight loss in the 18 to 22 percent range at high doses. The STEP trials for semaglutide showed roughly 12 to 15 percent. Now, these weren’t head-to-head trials (different populations, different protocols), so the comparison comes with a grain of salt. But the gap is consistent enough that most obesity medicine specialists consider it meaningful.
Here’s the thing: population averages don’t predict individual response all that well. Some people absolutely crush it on semaglutide. Some are underwhelmed by tirzepatide. Receptor sensitivity varies from person to person in ways researchers still haven’t fully mapped. What the aggregate data gives you is a starting point, not a verdict.
See also: Desert Fashion and Climate Influence
My Numbers, Side by Side
Semaglutide, nine months:
- Starting weight: 261 lbs
- Ending weight: 232 lbs
- Total loss: 29 lbs (11.1% of starting weight)
- Final dose: 2.0 mg weekly (the maximum at the time)
I stopped because the loss had flatlined for about ten weeks and there was nowhere left to go on the dose ladder. Gained 12 pounds back over the next four months before starting tirzepatide.
Tirzepatide, seven months:
- Starting weight: 244 lbs (post-regain)
- Current weight: 195 lbs
- Total loss: 49 lbs (20.1% of starting weight)
- Current dose: 7.5 mg weekly (mid-range)
Nearly double the percentage loss in less time. And I’m on a mid-range dose, meaning I still have room to titrate up if needed. That headroom alone is worth something psychologically.
Side Effects: Similar Catalog, Different Character
Both medications pull from roughly the same menu of side effects (nausea, GI issues, fatigue, constipation), but the texture is different.
Semaglutide gave me low-grade, persistent nausea. Not terrible on any given day, but always there, like background static. The fatigue was real and it lingered. Acid reflux was my worst symptom, probably because the gastric slowing effect was so sustained.
Tirzepatide hit harder during dose-up weeks. The jump to 5 mg and then 7.5 mg each brought two or three rough days of genuine nausea. But it cleared between doses in a way semaglutide never did. Fatigue was present but milder. Constipation was about equal on both. The GI effects were more intense early on, then settled.
If semaglutide is a dull headache that never quite leaves, tirzepatide is a sharper one that actually resolves. I’ll take the second pattern every time.
The Food Enjoyment Gap (The Part Nobody Talks About Enough)
This is the hardest thing to quantify and the most important thing to know if you plan to be on either medication long-term.
Semaglutide flattened my relationship with food. Not just hunger. Pleasure. Meals became transactional: you eat because the clock says so and your body needs fuel. A great steak and a mediocre protein bar registered about the same emotionally. It’s effective for weight loss, obviously. But after six months, food felt like a chore, and that’s a bleak way to live.
Tirzepatide suppresses hunger just as aggressively (more so, in my case), but it leaves more of the pleasure wiring intact. I eat less. I eat smaller portions. But when I sit down to a meal I actually chose because I wanted it, it still feels good. Favorite foods still land.
Why does this matter? Because sustainability. These medications work best when people stay on them for years, possibly indefinitely. If the drug makes food joyless, compliance becomes a grind. I’ve talked to at least a dozen people who used both, and the pattern is remarkably consistent: tirzepatide preserves more of the eating experience. Patient surveys hint at this, but it’s underrepresented in the clinical literature, which tends to measure pounds lost and HbA1c rather than whether dinner is still enjoyable.
Dose Flexibility and the Titration Experience
Semaglutide’s titration is slow and gentle. You walk from 0.25 mg up to 2.0 mg over about five months. It’s set-and-forget in the best sense. Fewer decisions, fewer inflection points.
Tirzepatide covers a wider range (2.5 mg to 15 mg over a similar timeframe) with more granular dose options. This means more control over the balance between efficacy and side effects, but also more conversations with your prescriber about whether to push the dose or hold. For someone who likes to optimize, this flexibility is a feature. For someone who just wants to take the shot and not think about it, it’s additional cognitive load.
What the Money Looks Like
Branded versions of both (Wegovy, Zepbound) run $1,000 to $1,400 per month at retail before insurance or manufacturer coupons. In my experience, insurance coverage for either is a coin flip at best.
Compounded versions of both tend to land between $200 and $450 monthly depending on provider, dose, and subscription terms. The price gap between compounded semaglutide and compounded tirzepatide is modest, usually $50 a month or less. Cost isn’t the deciding variable here. For a structured breakdown of the clinical evidence comparing both molecules, my prescriber pointed me toward compounded tirzepatide research at FormBlends, which lays out the SURMOUNT versus STEP trial data in a useful, side-by-side format.
Picking the Right One (Not the “Better” One)
There are real reasons to choose semaglutide over tirzepatide. Patients with cardiovascular disease, for instance, have the SELECT trial data behind semaglutide, showing actual cardiovascular event reduction. That outcome data doesn’t exist yet for tirzepatide. If you’ve responded well to semaglutide before, there’s no great reason to switch just because a newer option exists. And if you have a history of severe GI reactions, semaglutide’s gentler titration curve might save you some miserable weeks.
Tirzepatide tends to be the better fit when you’ve plateaued on semaglutide, when your starting BMI is high enough to benefit from the larger total loss the trials suggest, when preserving food enjoyment matters to your long-term adherence, or when you have type 2 diabetes and want the additional glycemic effects of the dual mechanism (though both medications produce substantial glycemic improvement).
What I’d Tell Myself Before Starting
If I could rewind, I’d have started on tirzepatide. For my profile specifically (high starting BMI, a plateau pattern on previous interventions, someone who really values eating as a positive part of life), it was the better molecule. I don’t think the nine months on semaglutide were wasted, but they were the scenic route.
This is not a universal recommendation. I know people who had the opposite experience, who felt better on semaglutide and found tirzepatide’s GI effects intolerable. The boring truth is that both medications work, both carry real side effects, and both require the same lifestyle changes alongside the pharmacotherapy. The difference between them is meaningful but secondary to a more fundamental question: are you treating obesity or not? Because the gap between either medication and doing nothing is far larger than the gap between the two.
Your prescriber is the right person to make this call with you. Bring your questions, bring your history, and ideally bring a clear picture of what “sustainable” looks like for your life, not just your next three months.
Frequently Asked Questions
Is tirzepatide more effective than semaglutide for weight loss? In clinical trials, tirzepatide produced higher average weight loss (18 to 22 percent at high doses in the SURMOUNT trials) compared to semaglutide (12 to 15 percent in the STEP trials). These weren’t direct head-to-head comparisons, so the numbers need context, but the trend is consistent. Individual response varies significantly.
Can I switch from semaglutide to tirzepatide? Yes, with prescriber guidance. Most providers recommend a brief washout period or a direct transition depending on your dose and response history. I transitioned with a four-month gap (unplanned), but many patients switch with only a week or two between.
Are the side effects worse on tirzepatide? Not categorically. Tirzepatide tends to produce more intense but shorter-duration side effects during titration, while semaglutide produces milder but more persistent ones. Neither is clearly “worse.” Your tolerance for acute vs chronic discomfort matters here.
Do compounded versions work the same as the branded medications? Compounded preparations use the same active molecules but are not FDA-approved products. They come from licensed compounding pharmacies and are prescribed based on individual clinical judgment. The active ingredient is identical; the manufacturing oversight pathway is different.
How long do I need to stay on either medication? Current evidence suggests that weight regain is common after discontinuation of either drug. Most obesity medicine specialists frame these as long-term or indefinite treatments, similar to blood pressure or cholesterol medications. The duration decision should be made with your prescriber based on your goals and response.
Is one medication safer than the other? Both have similar safety profiles in clinical trials. Semaglutide has a longer track record and more published cardiovascular outcome data (the SELECT trial). Tirzepatide’s long-term safety data is still accumulating. Neither has shown alarming safety signals in the published literature to date.
Does insurance cover one more often than the other? Coverage is inconsistent for both and varies widely by plan. Some insurers cover Wegovy but not Zepbound, or vice versa. Manufacturer savings programs exist for both branded versions. Compounded versions are typically cash-pay.
